1208007-67-3

Basic information

• Product Name: S-1-Pyrrolidinecarboxylic acid, 2-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethyleth
• Synonyms: S-1-Pyrrolidinecarboxylic acid, 2-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethyleth;(S)-2-(6-broMo-1h-benziMidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester;2-(6-Bromo-1H-benzimidazol-2-yl)-1-pyrrolidinecarboxylic acid 1,1-dimethylethyl ether;(S)-tert-butyl 2-(6-bromo-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate;(S)-tert-Butyl 2-(6-bromo-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate, 98%, ee: 98%
• CAS NO: 1208007-67-3
• Molecular Formula: C₁₆H₂₀BrN₃O₂
• Molecular Weight: 366.2529
• Mol File: 1208007-67-3.mol
• Article Data: 35

Chemical Properties

• Appearance: /
• CAS DataBase Reference: S-1-Pyrrolidinecarboxylic acid, 2-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethyleth(CAS DataBase Reference)
• NIST Chemistry Reference: S-1-Pyrrolidinecarboxylic acid, 2-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethyleth(1208007-67-3)
• EPA Substance Registry System: S-1-Pyrrolidinecarboxylic acid, 2-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethyleth(1208007-67-3)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 1208007-67-3(Hazardous Substances Data)

Usage

General Description

S-1-Pyrrolidinecarboxylic acid, 2-(6-bromo-1H-benzimidazol-2-yl)-, 1,1-dimethyleth is a chemical compound with potential pharmaceutical and therapeutic applications. It has been studied for its potential as a therapeutic agent for various diseases and conditions, including cancer and inflammatory disorders. The compound is a derivative of pyrrolidinecarboxylic acid and 6-bromo-1H-benzimidazole, and its 1,1-dimethyleth moiety may contribute to its pharmacological properties. Further research is needed to fully understand the compound's mechanism of action and potential medical uses.

Upstream product

• 59378-82-4 N-(tert-butoxycarbonyl)pyrrolidine-2-carboxaldehyde 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 147-85-3 L-proline 
• 1228553-72-7 (2S)-1-tert-butoxycarbonyl-2-(2-amino-4-bromophenylaminoacyl)pyrrolidine 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 1228553-72-7 C₁₆H₂₂BrN₃O₃ 
• 69610-41-9 Boc-L-Pro-H 
• 1228553-73-8 tert-butyl (S)-2-((2-amino-5-bromophenyl)aminoformyl)pyrrolidine-1-carboxylate 

Downstream Products

• 1228967-57-4 C₃₆H₄₂N₆O₄ 
• 1239649-66-1 C₄₄H₄₀N₆O₂ 
• 1228969-01-4 tert-butyl (2S)-2-[5-(4-bromophenyl)-1H-benzimidazol-2-yl]pyrrolidine-1-carboxylate 
• 1256385-57-5 (S)-tert-butyl 2-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1275033-97-0 C₃₉H₄₇N₅O₅ 
• 1275033-98-1 C₃₉H₄₇N₅O₅ 
• 1275019-54-9 C₃₄H₄₁N₅O₅ 
• 1275034-58-6 C₂₄H₂₅N₅O 
• 1275019-58-3 C₃₂H₄₁N₅O₅ 
• 1242087-93-9 ravidasvir 
• 1256386-36-3 (S)-tert-butyl 2-(6-(4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)biphenyl-4-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1256387-59-3 (S)-2-(acetoxyamino)-1-((S)-2-(6-(4-bromophenyl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)-3-methylbutan-1-one 
• 1256386-42-1 (S)-4-((2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1H-benzo[d]imidazol-6-yl)ethynyl)phenylboronic acid 
• 1532530-87-2 2-(6-{4-[2-(1-boc-pyrrolidin-2-yl)-3-(2-trimethylsilanylethoxymethyl)-3H-imidazol-4-yl]-phenylethynyl}-1H-benzoimidazol-2-yl)-pyrrolidine-1-carboxylic acid tertbutylester 

Relevant articles and documents

NOVEL BENZIMIDAZOLE DERIVATIVES

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

Fused tricyclic hepatitis virus inhibitor and application thereof

The invention belongs to the field of medical chemistry, relates to a fused tricyclic hepatitis virus inhibitor and application thereof, and particularly, provides a compound of the general formula I or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and a medicine composition containing the compounds and application of the compounds or the composition in medicine preparation. The compound has the good inhibiting activity on hepatitis C virus, meanwhile has the low toxicity on host cells, and is high in effectiveness, good in safety and likely to become the medicine for treating and/or preventing diseases relevant to HCV infection.